Study of a new medicine for graft-versus-host disease after ruxolitinib fails
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests an experimental medicine called gecacitinib for people who have graft-versus-host disease (GVHD) after a stem cell transplant and whose GVHD did not improve with standard second-line treatment (ruxolitinib). The goal is to see if this new treatment can help control GVHD symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have had a stem cell transplant (from a related or unrelated donor, or half-matched) at least once.
- Your donor cells must be working well (no more than 5% of your own cells remaining).
- You have acute graft-versus-host disease (GVHD) that did not get better, got worse, or came back after taking ruxolitinib.
- You must be able to take tablets by mouth and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
This study tests a new pill (gecacitinib) combined with steroids as the first treatment for moderate to severe acute graft-versus-host disease after a stem cell transplant. The goal is to see if this combination works better than steroids alone.
This study tests a new first-line therapy for patients who develop grade II acute graft-versus-host disease (GVHD) after their first stem cell transplant. It aims to find better ways to treat this complication.
This trial tests whether a new medication called gecacitinib can prevent a common complication after a stem cell transplant for myelofibrosis. The complication, called graft-versus-host disease, happens when donor cells attack the patient's body. The drug is given before and after the transplant.
This trial tests if ruxolitinib can help people with chronic graft-versus-host disease (cGvHD) that hasn't improved with steroids. It's for Chinese patients aged 12 and older who have moderate to severe cGvHD after a stem cell transplant.
This trial tests whether adding remestemcel-L (a type of cell therapy) to the standard drug ruxolitinib can help people with severe graft-versus-host disease (a complication after a stem cell transplant) that hasn't improved with steroids. The goal is to see if it can reduce symptoms and improve outcomes.
Hear when a new Acute Graft Versus Host Disease Grade II-IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.